CL2013003298A1 - Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. - Google Patents
Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo.Info
- Publication number
- CL2013003298A1 CL2013003298A1 CL2013003298A CL2013003298A CL2013003298A1 CL 2013003298 A1 CL2013003298 A1 CL 2013003298A1 CL 2013003298 A CL2013003298 A CL 2013003298A CL 2013003298 A CL2013003298 A CL 2013003298A CL 2013003298 A1 CL2013003298 A1 CL 2013003298A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- methotrexate
- autoimmunity
- administered
- diseases
- Prior art date
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229960000485 methotrexate Drugs 0.000 title abstract 2
- 230000005784 autoimmunity Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486697P | 2011-05-16 | 2011-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003298A1 true CL2013003298A1 (es) | 2014-07-25 |
Family
ID=47177257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003298A CL2013003298A1 (es) | 2011-05-16 | 2013-11-15 | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20140135337A1 (https=) |
| EP (2) | EP3824890A1 (https=) |
| JP (3) | JP6174572B2 (https=) |
| KR (3) | KR102163285B1 (https=) |
| CN (4) | CN103648501A (https=) |
| AU (1) | AU2012256281B2 (https=) |
| BR (1) | BR112013029501A2 (https=) |
| CA (1) | CA2835819A1 (https=) |
| CL (1) | CL2013003298A1 (https=) |
| CO (1) | CO6841993A2 (https=) |
| DO (1) | DOP2013000268A (https=) |
| EC (1) | ECSP13013081A (https=) |
| ES (1) | ES2836823T3 (https=) |
| GT (1) | GT201300278A (https=) |
| IL (2) | IL229245B (https=) |
| MA (1) | MA35165B1 (https=) |
| MX (1) | MX2013013445A (https=) |
| MY (1) | MY173304A (https=) |
| NI (1) | NI201300121A (https=) |
| PE (1) | PE20140469A1 (https=) |
| PH (1) | PH12013502256A1 (https=) |
| PT (1) | PT2709627T (https=) |
| RU (1) | RU2674036C2 (https=) |
| SG (1) | SG194802A1 (https=) |
| TN (1) | TN2013000472A1 (https=) |
| UA (1) | UA117556C2 (https=) |
| WO (1) | WO2012158362A1 (https=) |
| ZA (1) | ZA201308315B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011139379A2 (en) * | 2010-05-06 | 2011-11-10 | Duke University | A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| SG194802A1 (en) | 2011-05-16 | 2013-12-30 | Genzyme Corp | Induction of immune tolerance by using methotrexate |
| BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| BR112015030237A2 (pt) * | 2013-06-04 | 2017-10-03 | Selecta Biosciences Inc | Imunoterapêutico antígeno-específico, composição, método de fabricação e seu uso |
| JP7242180B2 (ja) | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| JP2016213236A (ja) * | 2015-04-30 | 2016-12-15 | 日東電工株式会社 | 半導体装置用フィルム、及び、半導体装置の製造方法 |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US11944628B2 (en) * | 2017-05-12 | 2024-04-02 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| TWI821227B (zh) * | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| MX2022009753A (es) | 2020-02-08 | 2022-09-07 | Genzyme Corp | Composiciones y metodos para el tratamiento de la enfermedad de pompe. |
| WO2022241259A1 (en) * | 2021-05-13 | 2022-11-17 | Genzyme Corporation | Novel predictive biomarkers for secondary autoimmunity after lymphocyte depleting therapy |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
| US4558690A (en) | 1982-01-26 | 1985-12-17 | University Of Scranton | Method of administration of chemotherapy to tumors |
| US5108987A (en) | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| DE4000154A1 (de) | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| CN1946743B (zh) | 2004-03-05 | 2010-06-02 | 电气化学工业株式会社 | 透明质酸/甲氨蝶呤化合物 |
| US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
| JP5722524B2 (ja) * | 2006-03-02 | 2015-05-20 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体活性を抑制することによる同種移植片の生存の延長 |
| WO2008094937A2 (en) | 2007-01-29 | 2008-08-07 | Joslin Diabetes Center, Inc. | Methods of modulating angiogenesis |
| WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| EP2077281A1 (en) * | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US7914785B2 (en) * | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| CA2740077A1 (en) | 2008-10-08 | 2010-04-15 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment |
| MX2011004870A (es) | 2008-11-07 | 2011-09-06 | 4Sc Ag | Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes. |
| SG194802A1 (en) | 2011-05-16 | 2013-12-30 | Genzyme Corp | Induction of immune tolerance by using methotrexate |
-
2012
- 2012-05-03 SG SG2013082003A patent/SG194802A1/en unknown
- 2012-05-03 US US14/116,486 patent/US20140135337A1/en not_active Abandoned
- 2012-05-03 CN CN201280035299.3A patent/CN103648501A/zh active Pending
- 2012-05-03 WO PCT/US2012/036405 patent/WO2012158362A1/en not_active Ceased
- 2012-05-03 PE PE2013002499A patent/PE20140469A1/es not_active Application Discontinuation
- 2012-05-03 ES ES12785624T patent/ES2836823T3/es active Active
- 2012-05-03 KR KR1020197033979A patent/KR102163285B1/ko active Active
- 2012-05-03 EP EP20197579.4A patent/EP3824890A1/en active Pending
- 2012-05-03 BR BR112013029501A patent/BR112013029501A2/pt not_active Application Discontinuation
- 2012-05-03 MX MX2013013445A patent/MX2013013445A/es unknown
- 2012-05-03 UA UAA201314626A patent/UA117556C2/uk unknown
- 2012-05-03 MY MYPI2013003998A patent/MY173304A/en unknown
- 2012-05-03 AU AU2012256281A patent/AU2012256281B2/en active Active
- 2012-05-03 CN CN202011422509.7A patent/CN113209288A/zh active Pending
- 2012-05-03 KR KR1020137032882A patent/KR20140040744A/ko not_active Ceased
- 2012-05-03 CN CN201910138372.3A patent/CN110124039A/zh active Pending
- 2012-05-03 CN CN201811398468.5A patent/CN109620830A/zh active Pending
- 2012-05-03 CA CA2835819A patent/CA2835819A1/en not_active Abandoned
- 2012-05-03 PH PH1/2013/502256A patent/PH12013502256A1/en unknown
- 2012-05-03 EP EP12785624.3A patent/EP2709627B1/en active Active
- 2012-05-03 JP JP2014511390A patent/JP6174572B2/ja active Active
- 2012-05-03 KR KR1020207027913A patent/KR102316283B1/ko active Active
- 2012-05-03 PT PT127856243T patent/PT2709627T/pt unknown
- 2012-05-03 RU RU2013155618A patent/RU2674036C2/ru active
-
2013
- 2013-11-04 IL IL229245A patent/IL229245B/en active IP Right Grant
- 2013-11-06 ZA ZA2013/08315A patent/ZA201308315B/en unknown
- 2013-11-13 TN TNP2013000472A patent/TN2013000472A1/fr unknown
- 2013-11-14 GT GT201300278A patent/GT201300278A/es unknown
- 2013-11-14 NI NI201300121A patent/NI201300121A/es unknown
- 2013-11-15 CL CL2013003298A patent/CL2013003298A1/es unknown
- 2013-11-15 DO DO2013000268A patent/DOP2013000268A/es unknown
- 2013-12-04 MA MA36522A patent/MA35165B1/fr unknown
- 2013-12-05 CO CO13286019A patent/CO6841993A2/es not_active Application Discontinuation
- 2013-12-13 EC ECSP13013081 patent/ECSP13013081A/es unknown
-
2017
- 2017-03-03 JP JP2017040046A patent/JP6381707B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145564A patent/JP6694020B2/ja active Active
-
2020
- 2020-03-24 US US16/828,407 patent/US11672802B2/en active Active
- 2020-08-23 IL IL276879A patent/IL276879B/en unknown
-
2023
- 2023-04-28 US US18/141,128 patent/US20230372347A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003298A1 (es) | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| CR20160278A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, asi como su uso para la preparación de medicamentos | |
| CL2017001364A1 (es) | Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos. | |
| DOP2015000100A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| CO6300949A2 (es) | Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
| MX370191B (es) | Composiciones y su uso en el tratamiento de la inmunodeficiencia. | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| PE20150190A1 (es) | Formulacion farmaceutica | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| UY36099A (es) | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad | |
| MX2019005309A (es) | Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| PH12015502655A1 (en) | Method | |
| BR112015028890A2 (pt) | derivados de piridona para o tratamento de infecções virais e outras doenças | |
| CL2010001594A1 (es) | Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida. | |
| MX389844B (es) | Regimen de dosificacion para interferon pegilado. |